Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
PMN ProMIS Neurosciences
4.959-0.201-3.90%
Close
02/03 16:00 ET
4.9590.0000.00%
Post Mkt Price 02/03 16:00 ET
High
5.260
Open
5.260
Turnover
8.88K
Low
4.940
Pre Close
5.160
Volume
1.77K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
ProMIS Neurosciences (NASDAQ:PMN) & Cingulate (NASDAQ:CING) Critical Survey
ProMIS Neurosciences (NASDAQ:PMN – Get Rating) and Cingulate (NASDAQ:CING – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses bas
ProMIS Neurosciences Management to Meet With Oppenheimer
ProMIS Neurosciences (OTCMKTS:ARFXF) Reaches New 52-Week High at $4.83
Shares of ProMIS Neurosciences, Inc. (OTCMKTS:ARFXF – Get Rating) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $4.83 and last traded at $4.78, with a vol
ProMIS Neurosciences Management to Meet Virtually With Oppenheimer
Financial Survey: ProMIS Neurosciences (OTCMKTS:ARFXF) Vs. ISpecimen (NASDAQ:ISPC)
ProMIS Neurosciences (OTCMKTS:ARFXF – Get Rating) and iSpecimen (NASDAQ:ISPC – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the
ProMIS Neurosciences (NASDAQ:PMN) Shares Up 1.3%
ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Rating)'s stock price traded up 1.3% on Friday . The company traded as high as $6.08 and last traded at $6.08. 818 shares were traded during mid-day trad
Leede Jones Gab Weighs in on ProMIS Neurosciences, Inc.'s FY2022 Earnings (TSE:PMN)
ProMIS Neurosciences, Inc. (TSE:PMN – Get Rating) – Research analysts at Leede Jones Gab boosted their FY2022 earnings per share estimates for shares of ProMIS Neurosciences in a research note issu
ProMIS Neurosciences (OTCMKTS:ARFXF) Hits New 12-Month High at $5.80
ProMIS Neurosciences, Inc. (OTCMKTS:ARFXF – Get Rating) hit a new 52-week high on Monday . The stock traded as high as $5.80 and last traded at $5.80, with a volume of 24 shares trading hands. The st
Reports Q3 Results
ProMIS Neurosciences Reports Q3 Net Loss US$6.0 Million
08:14 AM EST, 11/14/2022 (MT Newswires) -- ProMIS Neurosciences Inc. (PMN.TO), a biotechnology company, on Monday announced its Q3 2022 results. The company, which reports in US$, announced net loss w
Company Overview
More
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.
CEO： Dr. Gail M. Farfel, Pd.D
Market： NASDAQ
Listing Date： 07/08/2022
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet